Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Enzalutamide (Xtandi) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostatecancer (mHSPC). DSD: Horizon Scanning in Oncology 90. Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostatecancer (mHSPC) - Repository of AIHTA GmbH English | Browse - - - Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostatecancer (mHSPC) Rothschedl, E (...) . (2019): Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostatecancer (mHSPC). DSD: Horizon Scanning in Oncology 90. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 912kB Abstract Patients with metastatic hormone-sensitive prostatecancer (mHSPC) have never received androgen deprivation therapy (ADT) before, and thus are sensitive to ADT. Enzalutamide (Xtandi®) is an androgen receptor inhibitor, which
Prostatecancer: Scenario: Management of complications of prostatecancer and adverse effects of treatments Scenario: Complications and adverse effects | Management | Prostatecancer | CKS | NICE Search CKS… Menu Scenario: Complications and adverse effects Prostatecancer: Scenario: Management of complications of prostatecancer and adverse effects of treatments Last revised in October 2017 Scenario: Management of complications of prostatecancer and adverse effects of treatments How should I (...) follow up and monitor men with prostatecancer? Men with prostatecancer should be followed up in primary care in line with locally agreed protocols. For all men, review and manage: of the disease, including pain, lower urinary tract symptoms, and symptoms of spinal cord compression. Adverse effects from treatment, including and . Adverse effects of androgen withdrawal include change in body shape and weight gain, tiredness, hot flushes, loss of libido, erectile dysfunction, gynaecomastia, and loss
Radical Prostatectomy or Watchful Waiting in ProstateCancer - 29-Year Follow-up. Radical prostatectomy reduces mortality among men with clinically detected localized prostatecancer, but evidence from randomized trials with long-term follow-up is sparse.We randomly assigned 695 men with localized prostatecancer to watchful waiting or radical prostatectomy from October 1989 through February 1999 and collected follow-up data through 2017. Cumulative incidence and relative risks with 95 (...) % confidence intervals for death from any cause, death from prostatecancer, and metastasis were estimated in intention-to-treat and per-protocol analyses, and numbers of years of life gained were estimated. We evaluated the prognostic value of histopathological measures with a Cox proportional-hazards model.By December 31, 2017, a total of 261 of the 347 men in the radical-prostatectomy group and 292 of the 348 men in the watchful-waiting group had died; 71 deaths in the radical-prostatectomy group
Comparison of the Prognostic Utility of the Cell Cycle Progression Score for Predicting Clinical Outcomes in African American and Non-African American Men with Localized ProstateCancer Better prostatecancer risk stratification is necessary to inform medical management, especially for African American (AA) men, for whom outcomes are particularly uncertain.To evaluate the utility of both a cell cycle progression (CCP) score and a clinical cell-cycle risk (CCR) score to predict clinical outcomes (...) in a large cohort of men with prostatecancer highly enriched in an AA patient population.Patients were diagnosed with clinically localized adenocarcinoma of the prostate and treated at The Ochsner Clinic (New Orleans, LA, USA) from January 2006 to December 2011. CCP scores were derived from archival formalin-fixed, paraffin-embedded biopsy tissue. CCR scores were calculated as the combination of molecular (CCP score) and clinical (Cancer of the Prostate Risk Assessment [CAPRA] score) components.Active
Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostatecancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial The NRG/RTOG 9413 study showed that whole pelvic radiotherapy (WPRT) plus neoadjuvant hormonal therapy (NHT) improved progression-free survival in patients with intermediate-risk or high-risk localised prostatecancer compared with prostate only radiotherapy (PORT) plus NHT, WPRT plus adjuvant hormonal therapy (AHT), and PORT plus (...) in the NHT plus WPRT group, 17 (5%) of 313 in the NHT plus PORT group, 22 (7%) of 317 in the WPRT plus AHT group, and 14 (4%) of 315 in the PORT plus AHT group. Late grade 3 or worse gastrointestinal adverse events occurred in 22 (7%) of 316 patients in the NHT plus WPRT group, five (2%) of 313 in the NHT plus PORT group, ten (3%) of 317 in the WPRT plus AHT group, and seven (2%) of 315 in the PORT plus AHT group.In this cohort of patients with intermediate-risk and high-risk localised prostatecancer
Outcomes of Prostate-specific Antigen-based ProstateCancer Screening Among Men Using Nonsteroidal Anti-inflammatory Drugs. The Finnish Randomized Study of Screening for ProstateCancer (FinRSPC), the largest component of the European Randomized Study of Screening for ProstateCancer (ERSPC), showed a smaller, nonsignificant reduction in prostatecancer-specific mortality by systematic prostate-specific antigen (PSA)-based screening compared with the overall ERSPC results. Nonsteroidal anti (...) -inflammatory drugs (NSAIDs) reduce inflammation and also PSA elevations due to intraprostatic inflammation.To explore whether NSAID usage modifies the effects of PSA-based screening on prostatecancer incidence and mortality.A cohort of 78 165 men from the FinRSPC were linked to a comprehensive national prescription database to obtain information on NSAID reimbursements prior to screening.Prostate cancer risk and mortality were compared between the FinRSPC screening arm and the control arm among NSAID
A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade ProstateCancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy Discriminating indolent from clinically significant prostatecancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption.Performance and utility assessment of ExoDx Prostate (...) cohort in phase II will be reported separately.EPI is a noninvasive, easy-to-use, gene expression urine assay, which has now been successfully validated in over 1000 patients across two prospective validation trials to stratify risk of ≥GG2 from GG1 cancer and benign disease. The test improves identification of patients with higher grade disease and would reduce the total number of unnecessary biopsies.It is challenging to predict which men are likely to have high-grade prostatecancer (PCa
Hypofractionated Radiation Therapy for Localized ProstateCancer Hypofractionated Radiation Therapy for Localized ProstateCancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.18.01097 Journal of Clinical Oncology - published online before print October 11, 2018 Hypofractionated Radiation Therapy (...) for Localized ProstateCancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline x Scott C. Morgan , x Karen Hoffman , x D. Andrew Loblaw , x Mark K. Buyyounouski , x Caroline Patton , x Daniel Barocas , x Soren Bentzen , x Michael Chang , x Jason Efstathiou , x Patrick Greany , x Per Halvorsen , x Bridget F. Koontz , x Colleen Lawton , x C. Marc Leyrer , x Daniel Lin , x Michael Ray , and x Howard Sandler Scott C. Morgan, The Ottawa Hospital and University of Ottawa, Ottawa; D. Andrew Loblaw, Odette Cancer
A Meta-Analysis of Randomized Trials to Compare the Added Benefit of a Brachytherapy Boost Versus the Addition of Androgen Deprivation Therapy to External Beam Radiation Therapy in Men with Intermediate and High Risk ProstateCancer Redirecting
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostatecancer (STAMPEDE): a randomised controlled phase 3 trial. Based on previous findings, we hypothesised that radiotherapy to the prostate would improve overall survival in men with metastatic prostatecancer, and that the benefit would be greatest in patients with a low metastatic burden. We aimed to compare standard of care for metastatic prostatecancer, with and without radiotherapy.We did a randomised controlled phase (...) 3 trial at 117 hospitals in Switzerland and the UK. Eligible patients had newly diagnosed metastatic prostatecancer. We randomly allocated patients open-label in a 1:1 ratio to standard of care (control group) or standard of care and radiotherapy (radiotherapy group). Randomisation was stratified by hospital, age at randomisation, nodal involvement, WHO performance status, planned androgen deprivation therapy, planned docetaxel use (from December, 2015), and regular aspirin or non-steroidal
2018LancetControlled trial quality: predicted high
Early Detection of ProstateCancerProstateCancer: Early Detection Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students Exams/LLL (...) and Quality of Care Accreditations and Reporting Patient Education Early Detection of ProstateCancer (2018) Published 2013; Reviewed and Validity Confirmed 2018 The clinical guideline on Early Detection of ProstateCancer discusses the detection of disease at an early, pre-symptomatic stage through the use of screening tools, such as PSA. Early detection allows for more conservative management, if needed, via means such as active surveillance and watchful waiting. [pdf] Panel Members H. Ballentine Carter
Hypofractionated Radiation Therapy for Localized ProstateCancerProstateCancer: Hypofractionated Radiotherapy Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology (...) Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Hypofractionated Radiation Therapy for Localized ProstateCancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline (2018) Published 2018 The aim of this guideline is to present recommendations regarding moderately hypofractionated (240-340 cGy per fraction) and ultrahypofractionated (500 cGy or more per fraction) radiation therapy for localized prostatecancer. Panel Members Scott C
Castration-Resistant ProstateCancerProstateCancer: Castration Resistant Guideline - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis Retroperitoneum Cytology Online Learning For Medical Students (...) ) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Castration-Resistant ProstateCancer (2018) Published 2013; Amended 2018 Clinicians are challenged with a multitude of treatment options for patients with castration-resistant prostatecancer (CRPC). To assist in clinical decision-making, six index patients were developed representing the most common clinical scenarios that are encountered in clinical practice. With these patients in mind, guideline statements were
ASTRO/AUA Guideline on Hypofractionation for Localized ProstateCancer Supplemental Materials for Hypofractionated Radiation Therapy for Localized ProstateCancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline - Practical Radiation Oncology Email/Username: Password: Remember me Search Terms Search within Search Share this page: Volume 8, Issue 6, Pages 354–360 Hypofractionated Radiation Therapy for Localized ProstateCancer: Executive Summary of an ASTRO, ASCO, and AUA (...) period for guideline), Bayer (Joint Safety Review Committee; ended during disclosure period for guideline); Per Halvorsen: American College of Radiology Radiation Oncology Practice Accreditation program (honoraria, travel expenses); Karen Hoffman: Vanderbilt University (consultant); Patrick Greany: Department of Defense ProstateCancer Research Program (research funding, honoraria, travel expenses); Bridget Koontz: Janssen (research funding), Blue Earth Diagnostics (advisory board), American Society